4-甲氧羰基苯甲酰甲酸乙酯 | 155877-84-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-甲氧羰基苯甲酰甲酸乙酯
• 英文名称: ethyl <4-(methoxycarbonyl)benzoyl>acetate
• 英文别名: ethyl 4-(methoxycarbonyl)benzoylacetate；methyl 4-(2-ethoxycarbonylacetyl)benzoic acid；methyl 4-(3-ethoxy-3-oxopropanoyl)benzoate
• CAS: 155877-84-2
• 化学式: C₁₃H₁₄O₅
• 分子量: 250.251
• InChiKey: GFDCYWYWNSTMDX-UHFFFAOYSA-N

物化性质

• 沸点：
  363.8±22.0 °C(Predicted)
• 密度：
  1.181±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-甲氧羰基苯甲酰甲酸乙酯 在 sodium hydride 作用下， 以 xylene 为溶剂， 反应 3.0h， 生成 methyl 4-(1H-2,3,7,8,9,10-hexahydro-1,7,7,10,10-pentamethyl-2-oxonaphtho<2,3-b><1,4>diazepin-4-yl)benzoate
  参考文献：
  名称：

  Retinobenzoic Acids. 6. Retinoid Antagonists with a Heterocyclic Ring

  摘要：

  Several candidate retinoid antagonists were designed on the basis of the ligand superfamily concept and synthesized. Retinoidal activities of these benzimidazole and benzodiazepine derivatives were examined by assay of differentiation-inducing activity on human promyelocytic leukemia cell line HL-60. The parent benzimidazole derivative, 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylnapth[2,3-d]imidazol-2-yl)benzoic acid (7a), and related compounds with a small alkyl group instead of the hydrogen on the nitrogen (N-1) atom of the imidazole ring exhibited retinoidal activity, and the potency strongly depended on the bulkiness of the substituent. The compounds having a phenyl or benzyl group on the nitrogen lacked differentiation-inducing activity on HL-60 cells and acted as antagonists to the potent retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)carbamoyl]benzoic acid (Am80). Among the compounds possessing a seven-membered heterocyclic ring as a linking group, 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid (16) also exhibited the antagonistic activity. The binding abilities of these compounds to retinoic acid receptors ct and P were consistent with their potency for the inhibition of HL-60 cell differentiation induced by the retinoid Am80.

  DOI：

  10.1021/jm00036a017
• 作为产物：
  描述：

  4-氯甲酰基苯甲酸甲酯 在 ammonium hydroxide 、 sodium ethanolate 、 氯化铵 作用下， 反应 3.0h， 生成 4-甲氧羰基苯甲酰甲酸乙酯
  参考文献：
  名称：

  Retinobenzoic Acids. 6. Retinoid Antagonists with a Heterocyclic Ring

  摘要：

  Several candidate retinoid antagonists were designed on the basis of the ligand superfamily concept and synthesized. Retinoidal activities of these benzimidazole and benzodiazepine derivatives were examined by assay of differentiation-inducing activity on human promyelocytic leukemia cell line HL-60. The parent benzimidazole derivative, 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylnapth[2,3-d]imidazol-2-yl)benzoic acid (7a), and related compounds with a small alkyl group instead of the hydrogen on the nitrogen (N-1) atom of the imidazole ring exhibited retinoidal activity, and the potency strongly depended on the bulkiness of the substituent. The compounds having a phenyl or benzyl group on the nitrogen lacked differentiation-inducing activity on HL-60 cells and acted as antagonists to the potent retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)carbamoyl]benzoic acid (Am80). Among the compounds possessing a seven-membered heterocyclic ring as a linking group, 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid (16) also exhibited the antagonistic activity. The binding abilities of these compounds to retinoic acid receptors ct and P were consistent with their potency for the inhibition of HL-60 cell differentiation induced by the retinoid Am80.

  DOI：

  10.1021/jm00036a017

文献信息

• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120277224A1

  公开（公告）日：2012-11-01

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。
• Isoxazol-5(4H)one Derivatives as PTP1B Inhibitors Showing an Anti-Obesity Effect
  作者：Bhooshan Kafle、Nilkanth G. Aher、Deegendra Khadka、Hwangseo Park、Hyeongjin Cho

  DOI：10.1002/asia.201100154

  日期：2011.8.1

  prepared in a day by using the present protocol. The library compounds thus obtained were examined for their inhibitory activities against PTP1B. Among them, compound C3 was the most potent inhibitor of PTP1B with an IC50 of 2.3 μM. The in vivo effect of C3 was also examined in an obesity‐prone mouse strain. Diet‐induced obese (DIO)/diabetic mice were divided into two groups and each group was fed a

  在开发治疗性目标酶的抑制剂中，大量的时间和精力致力于大量化合物的制备。为了开发一种有效的蛋白酪氨酸磷酸酶（PTP）1B抑制剂作为抗肥胖和/或抗糖尿病药，我们使用简化的程序构建了一个异恶唑酮化学库，该程序避免了繁琐的后处理和纯化步骤。10×7异恶唑酮衍生物是通过将两半目标化合物偶联而合成的。当在试管中混合并加热时，前体产生的反应产物为沉淀物。短暂洗涤后，产物纯度足以用于酶促实验。通过制备用于偶联反应的前体，可以使用本方案在一天之内制备10×7库化合物。检查由此获得的文库化合物对PTP1B的抑制活性。其中，复合C3是PTP1B的最有效的抑制剂，其IC 50为2.3μ中号。还对易肥胖的小鼠品系中的C3进行了体内研究。饮食诱导的肥胖（DIO）/糖尿病小鼠分为两组，每组喂养高脂饮食（HFD）或HFD + C3，持续4周。与喂食HFD的对照组相比，在喂食期的四个星期内，C3喂食的小鼠组的体重显着减少。
• Antimalarial Pyrido[1,2-<i>a</i>]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model
  作者：Kawaljit Singh、John Okombo、Christel Brunschwig、Ferdinand Ndubi、Linley Barnard、Chad Wilkinson、Peter M. Njogu、Mathew Njoroge、Lizahn Laing、Marta Machado、Miguel Prudêncio、Janette Reader、Mariette Botha、Sindisiwe Nondaba、Lyn-Marie Birkholtz、Sonja Lauterbach、Alisje Churchyard、Theresa L. Coetzer、Jeremy N. Burrows、Clive Yeates、Paolo Denti、Lubbe Wiesner、Timothy J. Egan、Sergio Wittlin、Kelly Chibale

  DOI：10.1021/acs.jmedchem.6b01641

  日期：2017.2.23

  Further structure–activity relationship (SAR) studies on the recently identified pyrido[1,2-a]benzimidazole (PBI) antimalarials have led to the identification of potent, metabolically stable compounds with improved in vivo oral efficacy in the P. berghei mouse model and additional activity against parasite liver and gametocyte stages, making them potential candidates for preclinical development. Inhibition

  对最近鉴定出的吡啶并[1,2- a ]苯并咪唑（PBI）抗疟药的进一步结构-活性关系（SAR）研究已导致鉴定出有效的，代谢稳定的化合物，从而在伯氏疟原虫小鼠模型中具有改善的体内口服功效以及针对寄生虫肝脏和配子细胞阶段的额外活性，使其成为临床前开发的潜在候选者。抑制hezozoin的形成可能有助于其作用机理。
• C–H Activation-Based Traceless Synthesis via Electrophilic Removal of a Directing Group. Rhodium(III)-Catalyzed Entry into Indoles from <i>N</i>-Nitroso and α-Diazo-β-keto Compounds
  作者：Jie Wang、Mingyang Wang、Kehao Chen、Shanke Zha、Chao Song、Jin Zhu

  DOI：10.1021/acs.orglett.6b00310

  日期：2016.3.4

  A distinct C–H activation-based traceless synthetic protocol via electrophilic removal of a directing group is reported, complementing the currently exclusively used nucleophilic strategy. Rh(III)-catalyzed, N-nitroso-directed C–H activation allows the development of a traceless, atom- and step-economic, cascade approach for the synthesis of indole skeletons, starting from readily available N-nitroso

  据报道，通过亲电除去方向基团，可以得到一种独特的基于C H活化的无痕合成方案，该方案是对目前专门使用的亲核策略的补充。Rh（III）催化的，由N-亚硝基引导的C–H活化允许开发无痕，原子和步骤经济的级联方法来合成吲哚骨架，从易于获得的N-亚硝基和α-重氮化合物开始-β-酮化合物。重要的是，环化/脱亚硝化反应代表了迄今为止对于N-亚硝基的未观察到的反应模式。
• Aspergiolides A and B: Core Structural Establishment and Synthesis of Structural Analogues
  作者：Liang Qiao、Zhongwei Duan、Yinghan Chen、Yepeng Luan、Qianqun Gu、Yan-Kai Liu、Dehai Li

  DOI：10.1021/acs.joc.8b03185

  日期：2019.4.5

  The core structure of marine natural products aspergiolides A (1a) and B (1b) was achieved via a concise, two-step procedure with satisfactory yield. Based on this protocol, a natural products mimic library containing 25 structural simplified analogues of 1a was then constructed. Several prepared analogues showed potential cytotoxic activity against five different tumor cell lines, and compound 7bb

  海洋天然产物曲霉内酯A（1a）和B（1b）的核心结构是通过简洁的两步过程获得的，产率令人满意。基于该协议，然后构建了包含25个结构简化的1a类似物的天然产物模拟文库。几种制备的类似物显示出对五种不同肿瘤细胞系的潜在细胞毒性活性，尤其是化合物7bb，具有与1a相当的细胞毒性。